Does Mutual Pharmaceutical Co., Inc. v. Bartlett Herald the Demise of the "Failure-To-Withdraw" Theory?

In most states that use a “risk utility” test to determine whether a product is “not reasonably safe” (i.e. defective) as designed, an alternative design for the product is generally considered to be a critical element of the plaintiff’s proof. See, e.g., Restatement (Third) of Torts, § 2; Voss v. Black & Decker Mfg. Co., 59 N.Y.2d 102, 108, 7462 N.Y.S.2d 398, 402-03, 450 N.E.2d 204 (1983) (outlining New York’s risk utility approach). Where an alternative design cannot be claimed or argued, the argument is typically failure to warn. See, e.g., Liriano v. Hobart Corp., 92 N.Y.2d 232, 677 N.Y.S.2d 674, 700 N.E.2d 303 (N.Y. 1998) (manufacturers can be liable for failure-to-warn even if the substantial modification defense would preclude liability for design defect).

Where a plaintiff can argue neither alternative design nor failure to warn, one fall back position is that the product is so dangerous, and its danger so far exceeds its utility, that it ought not have been marketed at all. This theory, often called “failure-to-withdraw” or “stop-selling” theory, is typically an unappealing one for a plaintiff. Products enter the stream of distribution, and become successful, because of their utility. Presumably the plaintiff, plaintiff’s employer, or plaintiff’s doctor found the product to be useful, which is why the product was used. The more remote a plaintiff’s argument of danger or defect is, the less likely any court or jury is to allow for a liability finding. It is, in short, a big pronouncement for a court or jury to say, without proof of a feasible alternative design or a viable warning theory, that a product should be outright withdrawn from distribution. This fringe theory has been advanced as to certain types of guns, tobacco products, alcoholic beverages and, pertinent to this Alert, generic drugs.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

Published In:

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Schnader Harrison Segal & Lewis LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.